Art. -Nr.: HY-114483

AES-135

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC₅₀s ranging from 190-1100 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.68%
CAS. Nr.: 2361659-61-0
Formel: C₃₃H₂₉F₆N₃O₅S
Molecular Weight:693.66

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

AES-135 Chemical Structure

CAS. Nr.: 2361659-61-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HDAC6

190 nM (IC₅₀)

HDAC11

636 nM (IC₅₀)

HDAC3

654 nM (IC₅₀)

HDAC8

1100 nM (IC₅₀)

Alle HDAC Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	IC₅₀	2.62 μM Compound: 5; AES-135	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MDA-MB-231	IC₅₀	2.72 μM Compound: AES-135	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay	[PMID: 30776234]
MDA-MB-468	IC₅₀	4.21 μM Compound: 5; AES-135	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MOLM-13	IC₅₀	2.1 μM Compound: 5; AES-135	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MV4-11	IC₅₀	1.88 μM Compound: 5; AES-135	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MV4-11	IC₅₀	1.88 μM Compound: AES-135	Cytotoxicity against human MV4-11 cells after 72 hrs by CellTiter-Blue assay Cytotoxicity against human MV4-11 cells after 72 hrs by CellTiter-Blue assay	[PMID: 30776234]
Pa03C	IC₅₀	1.22 μM Compound: AES-135	Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid area after 72 hrs by Alamar Blue assay Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid area after 72 hrs by Alamar Blue assay	[PMID: 30776234]
Pa03C	IC₅₀	1.33 μM Compound: AES-135	Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay	[PMID: 30776234]
Pa03C	IC₅₀	1.41 μM Compound: AES-135	Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid area after 72 hrs in presence of human CAF19 cells by Alamar Blue assay Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid area after 72 hrs in presence of human CAF19 cells by Alamar Blue assay	[PMID: 30776234]
Pa03C	IC₅₀	1.56 μM Compound: AES-135	Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid intensity after 72 hrs in presence of human CAF19 cells by Alamar Blue assay Cytotoxicity against human Pa03C cells assessed as reduction in tumor spheroid intensity after 72 hrs in presence of human CAF19 cells by Alamar Blue assay	[PMID: 30776234]
Pa03C	IC₅₀	3.4 μM Compound: AES-135	Cytotoxicity against human Pa03C monolayer cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay Cytotoxicity against human Pa03C monolayer cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay	[PMID: 30776234]
Panc1005	IC₅₀	0.5 μM Compound: AES-135	Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid intensity after 72 hrs in presence of human CAF19 cells by Alamar Blue assay Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid intensity after 72 hrs in presence of human CAF19 cells by Alamar Blue assay	[PMID: 30776234]
Panc1005	IC₅₀	0.6 μM Compound: AES-135	Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay	[PMID: 30776234]
Panc1005	IC₅₀	0.94 μM Compound: AES-135	Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid area after 72 hrs in presence of human CAF19 cells by Alamar Blue assay Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid area after 72 hrs in presence of human CAF19 cells by Alamar Blue assay	[PMID: 30776234]
Panc1005	IC₅₀	0.97 μM Compound: AES-135	Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid area after 72 hrs by Alamar Blue assay Cytotoxicity against human Panc 10.05 cells assessed as reduction in tumor spheroid area after 72 hrs by Alamar Blue assay	[PMID: 30776234]
Panc1005	IC₅₀	3.9 μM Compound: AES-135	Cytotoxicity against human Panc 10.05 monolayer cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay Cytotoxicity against human Panc 10.05 monolayer cells assessed as reduction in tumor spheroid intensity after 72 hrs by Alamar Blue assay	[PMID: 30776234]
Sf9	IC₅₀	>1 μM Compound: 5; AES-135	Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	>1 μM Compound: AES-135	Inhibition of recombinant human HDAC8 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA Inhibition of recombinant human HDAC8 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA	[PMID: 30776234]
Sf9	IC₅₀	0.19 μM Compound: 5; AES-135	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.19 μM Compound: AES-135	Inhibition of recombinant human HDAC6 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA Inhibition of recombinant human HDAC6 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA	[PMID: 30776234]
Sf9	IC₅₀	0.636 μM Compound: 5; AES-135	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.636 μM Compound: AES-135	Inhibition of recombinant human HDAC11 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA Inhibition of recombinant human HDAC11 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA	[PMID: 30776234]
Sf9	IC₅₀	0.654 μM Compound: 5; AES-135	Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.654 μM Compound: AES-135	Inhibition of recombinant human HDAC3 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA Inhibition of recombinant human HDAC3 expressed in SF9 baculoviral system using FAM-labeled acetylated peptide as substrate by EMSA	[PMID: 30776234]

In Vitro

AES-135 inhibits cancer cells growth with IC₅₀ values of 2.3 μM, 1.4 μM, 0.27 μM, 0.94 μM, 1.9 μM, 2.72 μM, 2.1 μM, 15.0 μM, 1.6 μM and 19.2 μM for BT143, BT189, D425, D458, MV4-11, MOLM-13, MDA-MB-231, K562, PC-3 and MRC-9 cells, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AES-135 (50 mg/kg; intraperitoneal injection; 5 days a week; for 1 month) treatment significantly increases survival of C57Bl/6 mice implanted with KPC2 cells^[1].
NSG mice are dosed with a single 20 mg/kg intraperitoneal (IP) injection, and blood is taken at 0.5 h, 1 h, 2 h, 4 h, 8 h, and 24 h. AES-135 achieved μM concentrations in the blood, reaching C_max 7452 ng/mL (10.74 μM) within 30 min, which is sustained for 8 h. The blood concentration of AES-135 is dose dependent, achieving an average of 323 ng/mL (0.47 μM) with 10 mg/kg dosing and 1829 ng/mL (2.64 μM) with 40 mg/kg. AES-135 shows an impressive pharmacokinetic profile in mice with an in vivo half-life of 5.0 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57Bl/6 mice injected with KPC2 cells^[1]
Dosage:

50 mg/kg
Administration:

Intraperitoneal injection; 5 days a week; for 1 month
Result:

Significantly increased survival of mice.

Chemical Information

CAS. Nr. 2361659-61-0
Appearance Solid
Molecular Weight 693.66
Formel C₃₃H₂₉F₆N₃O₅S
Color White to off-white
SMILES

CC(C)(C)C1=CC=C(CN(C(CN(CC2=C(F)C(F)=C(F)C(F)=C2F)S(=O)(C3=CC=C(F)C=C3)=O)=O)C4=CC=C(C(NO)=O)C=C4)C=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Cell Death Dis

IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. [Abstract]

2021 May 18;12(6):501. PMID: 34006836
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (144.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4416 mL

7.2081 mL

14.4163 mL

5 mM

0.2883 mL

1.4416 mL

2.8833 mL

10 mM

0.1442 mL

0.7208 mL

1.4416 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shouksmith AE, et al. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem. 2019 Mar 14;62(5):2651-2665. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4416 mL	7.2081 mL	14.4163 mL	36.0407 mL
	5 mM	0.2883 mL	1.4416 mL	2.8833 mL	7.2081 mL
	10 mM	0.1442 mL	0.7208 mL	1.4416 mL	3.6041 mL
	15 mM	0.0961 mL	0.4805 mL	0.9611 mL	2.4027 mL
	20 mM	0.0721 mL	0.3604 mL	0.7208 mL	1.8020 mL
	25 mM	0.0577 mL	0.2883 mL	0.5767 mL	1.4416 mL
	30 mM	0.0481 mL	0.2403 mL	0.4805 mL	1.2014 mL
	40 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9010 mL
	50 mM	0.0288 mL	0.1442 mL	0.2883 mL	0.7208 mL
	60 mM	0.0240 mL	0.1201 mL	0.2403 mL	0.6007 mL
	80 mM	0.0180 mL	0.0901 mL	0.1802 mL	0.4505 mL
	100 mM	0.0144 mL	0.0721 mL	0.1442 mL	0.3604 mL

Keywords

AES-135

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AES-135

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) AES-135

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AES-135

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) AES-135

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AES-135 Related Classifications

HY-114483 Related Classifications